Anticancer maytansinoids with two fused macrocyclic rings
This invention provides maytansinoids having improved tumor inhibition activity. In particular, the present invention provides a method of treatment of cancer, in particular colon cancer, using maytansinoid compounds having two fused macrocyclic rings.
1. A method of treating cancer, comprising: administering daily a composition comprising an effective dose of at least one compound selected from the group consisting of
wherein R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen and an alkyl group having 1 to 6 carbon atoms,
and
wherein R is CH 2 CH 2 CH 3 .
2. The method according to claim 1 , wherein the effective dosage is at least 1.6 μg/kg per patient body weight.
3. The method according to claim 1 , wherein the effective dosage is about 3.2 μg/kg per patient body weight.
4. The method according to claim 1 , wherein the effective dosage is about 0.004 mg/kg per patient body weight.
5. The method according to claim 1 , wherein the effective dosage is about 20 μg/kg per patient body weight.
6. The method according to claim 1 , wherein the effective dosage is about 40 μg/kg per patient body weight.
7. The method according to claim 1 , wherein the effective dosage is about 0.05 mg/kg per patient body weight.
8. The method according to claim 1 , wherein the cancer treated is colon carcinoma.
9. The method according to claim 1 , wherein the cancer treated is oral epidermoid carcinoma.
10. The method according to claim 1 , wherein the cancer treated is promyelocytic leukemia.
11. The method according to claim 1 , wherein the cancer treated is prostate carcinoma.
12. The method according to claim 1 , wherein the cancer treated is breast carcinoma.
13. The method according to claim 1 , wherein the cancer treated is lung carcinoma.
14. The method according to claim 1 , wherein the compound is a compound of Formula III: